Genentech yanks Gavreto’s rare thyroid cancer indication, months before handing it back to Blueprint

Roche subsidiary Genentech is yanking Gavreto’s accelerated approval for a type of thyroid cancer after determining a confirmatory study is no longer feasible.

The kinase inhibitor, also known as pralsetinib, will no longer be available to adults and kids 12 years and up with advanced or metastatic rearranged during transfection…
Click here to view original post